NCT06823947

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Kyowa Kirin Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension. Part 3 : To assess the safety profile of repeated dosing of KK3910 in an additional hypertension cohort.

Conditions

• Healthy Volunteers Essential Hypertension

Interventions

Type	Name	Description
DRUG	Placebo	Placebo is administered single dose or multiple dose by SC injection.
DRUG	KK3910	KK3910 is administered single dose or multiple dose by SC injection.

Timeline

• Start date: 2025-04-03
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-02-12
• Last updated: 2026-03-09

Locations

3 sites across 1 country: Japan